Burzynski Research Institute Inc's Competitiveness
A competitive positioning analysis and financial ratio benchmarking of Burzynski Research Institute Inc (BZYR) against its publicly traded competitors: sales growth, net income, profitability, valuation and market share, plus each peer's market capitalization, revenue, income and employees. Free below: the top 5 peers. Subscriber access adds the full competitor list and CSV downloads.
Key Findings: Burzynski Research Institute Inc vs Its Competitors
- Scale: Burzynski Research Institute Inc ranks #18 of 19 companies by market capitalization in the In Vitro & In Vivo Diagnostic Substances industry, holding 0.0% of industry market cap.
Every figure above is sourced and cited in detail further down this page (Market Structure, Profitability & Cost Structure, Productivity vs Peers).
API endpoints for this dataset
Burzynski Research Institute Inc's Competitor Quality Breadth
Group definitions: see Methodology: Performance Group Definitions.
| Entity | Profitable | Expanding | Above Industry Growth | Distressed |
|---|---|---|---|---|
| Burzynski Research Institute Inc | - | - | - | Yes |
| Competitors combined (10) | ||||
| Similar-Size Competitors (5) |
Source: CSIMarket API, trailing 12 months. Altman Z-Score is not shown here: it is not populated in the underlying data for any company. Percentages are of companies in each group that report the relevant metric, not of the full group size.
BZYR Stock Performance relative to its Competitors
BZYR Stock Performance relative to Similar-Size Competitors
5 Best-Performing Tracked Competitors, Trailing 12 Months
| # | Competitor | TTM Share Price Return | vs U.S.A. 500 |
|---|---|---|---|
| 1 | Moderna Inc | 282.9% | Outperformed |
| 2 | Illumina Inc | 282.9% | Outperformed |
| 3 | Biogen Inc | 282.9% | Outperformed |
| 4 | Regeneron Pharmaceuticals Inc | 282.9% | Outperformed |
| 5 | Amgen Inc | 282.9% | Outperformed |
TTM share price return and U.S.A. 500 outperformance for Burzynski Research Institute Inc's best-performing competitors requires a Commercial License.
Source: CSIMarket API, trailing 12 months.
Burzynski Research Institute Inc's Comment on Competition and Industry Peers
Publicly Traded Peers of Burzynski Research Institute Inc
Revenue and income for trailing 12 months, in millions of $, except employees| Company | Market Cap | Revenues |
|---|---|---|
 Burzynski Research Institute Inc |
0.03 | - |
 Amgen Inc |
254,255.82 | 38,903.00 |
 Gilead Sciences Inc |
210,268.08 | 30,988.00 |
 Vertex Pharmaceuticals Inc |
137,450.72 | 12,951.60 |
 Regeneron Pharmaceuticals Inc |
100,897.63 | 16,896.20 |
 Moderna Inc |
88,901.26 | 2,228.00 |
| SUBTOTAL | 864,775.62 | 117,219.54 |
Sign in to see all competitors of Burzynski Research Institute Inc.
Sources: see Methodology: Peer & Competitor Identification, Sourcing.
Updated on:
Focus of this report: publicly traded companies. Ten additional tables on Burzynski Research Institute Inc versus competitors, including market share analysis, are in the navigation menu under Competition. To download the tables, please subscribe.
Burzynski Research Institute Inc's Business Segment Mix vs Peers
Revenue by operating segment or division, as named and reported by each company. Segment names are the filer's own and are not standardized across companies. Do not assume a same-named or similarly-named segment is defined identically between two companies. Shares are of each company's own total revenue and are not required to sum to 100% (intersegment revenue, unallocated items).| Company | Largest Segment |
|---|---|
| Amgen Inc | Reportable 100.00 % |
| Vertex Pharmaceuticals Inc | Pharmaceuticals 100.00 % |
| Biogen Inc | Reportable 100.00 % |
| Illumina Inc | Sequencing 90.43 % |
| Novavax inc | Reportable 100.00 % |
Source: operating segment revenue as reported in each company's reports (10-K/10-Q), via the CSIMarket API, leaf-level reportable segments only (parent roll-up segments are excluded where sub-segments are separately disclosed).
Burzynski Research Institute Inc's Productivity vs Peers Comparison
Revenue and income per employee, trailing 12 months, in $; market cap in millions of $| Company | Market Cap | Revenue / Employee | Income / Employee |
|---|---|---|---|
| Burzynski Research Institute Inc | 0 | - | - |
| Amgen Inc | 254,256 | 2,992,538 | 722,385 |
| Gilead Sciences Inc | 210,268 | 1,822,824 | -227,235 |
| Vertex Pharmaceuticals Inc | 137,451 | 31,979,259 | 9,817,037 |
| Regeneron Pharmaceuticals Inc | 100,898 | 1,096,444 | 312,615 |
| Moderna Inc | 88,901 | 474,043 | -670,426 |
| PEERS TOTAL | 864,776 | 1,943,617 | 196,890 |
Sign in to see all peers for Burzynski Research Institute Inc.
Burzynski Research Institute Inc's Geographic Revenue Exposure vs Peers
Revenue by country/region as reported in each company's most recent report. Disclosure granularity varies by filer (some report by country, others by broad region) and is shown as disclosed.| Company | Largest Market |
|---|---|
| Gilead Sciences Inc | United States 76.66 % |
| Vertex Pharmaceuticals Inc | United States 63.04 % |
| Illumina Inc | United States and Canada 56.42 % |
| Novavax inc | United States 68.88 % |
Source: revenue geography as reported in each company's reports (10-K/10-Q), via the CSIMarket API. Percentages are of that company's own total consolidated revenue for its most recent reported period.
Burzynski Research Institute Inc's Position in Industry Market Structure
Market-capitalization share and concentration across all 18 companies in Burzynski Research Institute Inc's industry classification, broader than the peer set above. Market cap in millions of $.Burzynski Research Institute Inc ranks #18 of 18 companies by market capitalization in its industry, holding 0.00 % of total industry market cap. The industry's Herfindahl-Hirschman Index (HHI) is 6,085, indicating a highly concentrated market structure (see Methodology: Market Structure & Concentration).
| Rank | Company | Market Cap | Industry Share |
|---|---|---|---|
| 1 | Idexx Laboratories Inc | 55,854 | 77.24 % |
| 2 | Lantheus Holdings Inc | 6,859 | 9.49 % |
| 3 | Neogen Corporation | 2,443 | 3.38 % |
| 4 | Celldex Therapeutics inc | 2,244 | 3.10 % |
| 5 | Intellia Therapeutics Inc | 1,234 | 5.2% |
| 6 | Trinity Biotech Plc | 1,234 | 5.2% |
| 7 | Quidelortho Corp | 1,234 | 5.2% |
| 8 | Achieve Life Sciences Inc | 1,234 | 5.2% |
| 9 | Myriad Genetics Inc | 1,234 | 5.2% |
| 10 | Alpha Teknova Inc | 1,234 | 5.2% |
| 18 | Burzynski Research Institute Inc | 0 | 0.00 % |
Market cap and industry share for the rest of Burzynski Research Institute Inc's industry peers requires a Commercial License.
Source: CSIMarket API (daily market-structure computation) across CSIMarket's industry classification, market capitalization as of 2026-11-12.
Burzynski Research Institute Inc's Same-Size Peers & Stock Performance
Peers chosen by closeness in market-cap rank within the same industry classification (not the named-competitor list above). Trailing 12-month total return, 3-month price momentum, beta and Sharpe ratio vs the broad U.S. market.| Rank | Company | Market Cap | TTM Return |
|---|---|---|---|
| 13 | Aspira Women s Health inc | 8 | - |
| 14 | Cardio Diagnostics Holdings Inc | 6 | -47.33 % |
| 15 | Biomerica Inc | 1,234 | 12.3% |
| 16 | Qc Technologies Inc | 1,234 | 12.3% |
| 17 | Volitionrx Limited | 1,234 | 12.3% |
| 18 | Burzynski Research Institute Inc | 0 | - |
Market cap, return, momentum, beta and Sharpe ratio for the rest of Burzynski Research Institute Inc's same-size peers requires a Commercial License.
Source: CSIMarket API (daily market-structure computation); returns and risk metrics as of 2026-11-13. Beta and Sharpe ratio are versus the broad U.S. equity market, not this industry.
Burzynski Research Institute Inc's Valuation vs Competitive Position
Valuation multiples vs the In Vitro & In Vivo Diagnostic Substances industry average (22 companies, excluding loss-making/negative-equity outliers), alongside returns on capital for context on whether a premium or discount lines up with measurably stronger or weaker returns. See the full In Vitro & In Vivo Diagnostic Substances industry valuation benchmarks.| Metric | Company | Industry Average | Difference |
|---|---|---|---|
| P/E | - | 39.1x | - |
| EV / EBITDA | - | 16.5x | - |
| P/B | -81.8x | 4.1x | -85.9x |
| Return on Equity | - | industry aggregate | - |
| Return on Invested Capital | - | -7.17 % (avg) | - |
Source: CSIMarket API, trailing 12 months. A valuation premium or discount is not, by itself, a judgment of over- or under-valuation. Compare it against the return and growth context shown elsewhere on this page.
Burzynski Research Institute Inc's Multi-Year Financial Trajectory
Fiscal-year revenue growth, operating margin, return on invested capital and P/E, as reported in company reports.| Metric | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|
| Revenue Growth | - | - | - | - | - | - | - | - |
| Operating Margin | - | - | - | - | - | - | - | - |
| Return on Invested Capital | - | - | - | - | - | - | - | - |
| P/E | - | - | - | - | - | - | - | - |
Source: CSIMarket API, fiscal-year figures. P/E is this company's own historical ratio at each fiscal year end and can swing sharply around an earnings trough: that is real, not a data error.
Burzynski Research Institute Inc's BCG Growth-Share Matrix
See Methodology: BCG Growth-Share Matrix for how relative share and growth are calculated and thresholded.
Burzynski Research Institute Inc falls in the Dog quadrant: relative market share of 0.00x vs its largest competitor, in an industry growing revenue -2.8% (median, trailing 12 months).
Source: CSIMarket API (market-cap share and industry revenue growth). The 10% growth and 1.0x share lines are standard textbook thresholds, not derived from this industry's own distribution. A caveat worth reading alongside this chart: Idexx Laboratories Inc alone holds 77% of this industry's market cap. In an industry this dominated by one leader, the framework will place nearly every OTHER company in "Dog" or "Question Mark" purely because relative share is measured against that leader, regardless of how strong those other companies actually are on their own fundamentals. Check the Profitability, Valuation and Financial Strength sections above before treating this quadrant label as a verdict.
Burzynski Research Institute Inc's Competitive Forces (Porter's Five Forces)
Only the forces this data can support honestly are shown; the other three are marked as such rather than guessed.| Force | Assessment | Basis |
|---|---|---|
| Competitive Rivalry | Low | Industry HHI of 6,085 (see Industry Market Structure & Concentration above) |
Note: see Methodology: Porter's Five Forces. Supplier power and buyer power are covered on Burzynski Research Institute Inc's dedicated Suppliers and Customers pages, not here.
Burzynski Research Institute Inc's Industry Attractiveness & Competitive Strength
See Methodology: GE/McKinsey Matrix for how the two axes are built.
Burzynski Research Institute Inc falls in the Medium attractiveness / Low strength cell: Harvest.
Source: CSIMarket API, trailing 12 months. Each axis score is a simple 1(low)/2(medium)/3(high) average across its three inputs -- a transparent, disclosed simplification, not a validated academic scoring model.
Burzynski Research Institute Inc's SWOT
Every point below is a fixed rule applied to a metric already shown elsewhere on this page (Market Structure, Profitability, Valuation, Run-Rate, Stock Performance, Quality Breadth) not an independent strategic assessment. A blank quadrant means no rule was met, not that none apply.Strengths
No rule matched.
Weaknesses
- Low relative market share vs the industry leader (0.00x).
- Piotroski F-Score of 2 or below, the standard financial-distress signal.
Opportunities
- A meaningful share of competitors (30.00 %) show financial-distress signals, a possible opening to gain share.
Threats
- Industry dominated by Idexx Laboratories Inc, holding 77.24 % of industry market cap.
Methodology: see Methodology: SWOT Analysis.
Burzynski Research Institute Inc's Financial Strength vs Peers Comparison
Quick ratio, working capital, debt to equity and asset turnover, trailing 12 months| Company | Quick Ratio | Working Capital | Debt / Equity |
|---|---|---|---|
| Burzynski Research Institute Inc | 0.02 | 0.02 | - |
| Amgen Inc | 0.49 | 1.31 | 5.27 |
| Gilead Sciences Inc | - | 1.52 | 1.47 |
| Vertex Pharmaceuticals Inc | 1.30 | 2.83 | 0.06 |
| Regeneron Pharmaceuticals Inc | 0.58 | 3.56 | 0.06 |
| Moderna Inc | 0.86 | 2.88 | 0.07 |
Sign in to see all peers for Burzynski Research Institute Inc.
Quick ratio = cash / current liabilities; working capital ratio = current assets / current liabilities; asset turnover = revenue / total assets. Peers in the Blank Checks industry are excluded.
Burzynski Research Institute Inc's Revenue and Income Growth vs Peers
Quarterly revenue and net income growth, year over year and quarter over quarter| Company | Period | Revenue Y/Y | Income Y/Y |
|---|---|---|---|
| Burzynski Research Institute Inc | Q4 2025 | - | - |
| Amgen Inc | Q3 2026 | +8.5 % | +20.1 % |
| Gilead Sciences Inc | Q3 2026 | +6.8 % | -20.4 % |
| Vertex Pharmaceuticals Inc | Q3 2026 | +11.8 % | -39.6 % |
| Regeneron Pharmaceuticals Inc | Q3 2026 | +36.3 % | +33.5 % |
| Moderna Inc | Q2 2026 | +2.1 % | - |
| PEERS TOTAL | +12.1 % | -1.8 % |
Sign in to see all peers for Burzynski Research Institute Inc.
Growth is shown only where both periods are positive. Peers in the Blank Checks industry are excluded.
Burzynski Research Institute Inc's Peers' Costs of Sales and Capital Expenditures
Context for revenue growth: peer costs and capex, year over year and quarter over quarter| Company | Period | Costs Y/Y | Capex Y/Y |
|---|---|---|---|
| Burzynski Research Institute Inc | Q4 2025 | - | - |
| Amgen Inc | Q3 2026 | -9.5 % | +34.6 % |
| Gilead Sciences Inc | Q3 2026 | +0.1 % | +61.2 % |
| Vertex Pharmaceuticals Inc | Q3 2026 | +26.8 % | -4.4 % |
| Regeneron Pharmaceuticals Inc | Q3 2026 | +104.1 % | +49.1 % |
| Moderna Inc | Q2 2026 | -21.8 % | +1,133.3 % |
Sign in to see all peers for Burzynski Research Institute Inc.
Burzynski Research Institute Inc's Returns and Turnover vs Peers
ROA, ROI and ROE (trailing 12 months), receivables and inventory turnover| Company | ROA | ROI | ROE |
|---|---|---|---|
| Burzynski Research Institute Inc | - | - | - |
| Amgen Inc | 10.02% | 13.64% | 85.59% |
| Gilead Sciences Inc | - | - | - |
| Vertex Pharmaceuticals Inc | 14.16% | 16.63% | 20.08% |
| Regeneron Pharmaceuticals Inc | 11.50% | 13.00% | 15.07% |
| Moderna Inc | - | - | - |
Sign in to see all peers for Burzynski Research Institute Inc.
ROA = net income / total assets; ROI = net income / investments; ROE = net income / equity; turnover ratios use trailing 12 month revenue (receivables) and cost of sales (inventory).
Burzynski Research Institute Inc's Valuation vs Peers
P/E, price to sales, PEG, price to cash flow and price to book| Company | P/E | Price / Sales |
|---|---|---|
| Burzynski Research Institute Inc | - | - |
| Amgen Inc | 27.00 | 6.54 |
| Gilead Sciences Inc | - | 6.79 |
| Vertex Pharmaceuticals Inc | 34.73 | 10.61 |
| Regeneron Pharmaceuticals Inc | 21.13 | 5.97 |
| Moderna Inc | - | 39.90 |
| PEERS AVERAGE | 72.83 | 7.38 |
Sign in to see all peers for Burzynski Research Institute Inc.
P/E = price / diluted EPS (trailing 12 months); PEG = P/E divided by EPS growth; the average row divides the peers' combined market cap by their combined income, sales, cash flow and equity.